Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Month: September 2018
S7 plots trajectory of $50m fund
Russia-based air carrier S7 Airlines is lining up a $50m fund having already tested the waters with $10m of corporate venturing investments.
IDx identifies corporates to raise $33m
The diabetes diagnosis technology developer harnessed Heritage Provider Network and Optum Ventures for its latest round.
Compass finds $400m in series F round
SoftBank Vision Fund, which invested $450m in Compass in December, returned to co-lead a series F round that valued it at $4.4bn.
Fosun catches Butterfly in $250m series D
Fosun Pharma has contributed to a $250m series D round for medical device maker Butterfly Network, valuing the company at $1.25bn.
SoftBank bids to invest in ByteDance
SoftBank is reportedly among the interested investors as digital media company ByteDance targets $3bn at a $75bn valuation.
Invenergy’s CVC arm converts to $150m Energize fund
Invenergy Future Fund has been rebranded as Energize Ventures and closed a $150m fund that includes GE, Schneider Electric and WEC Energy as LPs.
Viomi connects to Nasdaq in flotation
The home IoT platform floated at the foot of its range to raise almost $103m, while Xiaomi will retain a 16.4% stake in the company.
Entasis enters public markets with $75m
The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.
Liqid gets series C investment
The Berliner Volksbank-backed digital wealth manager has secured almost $39m in a Toscafund-led funding round.
Ceribell seizes $35m
The EEG system developer raised the series B funding from investors including UCB and LivaNova and will use it commercialise its lead device.
CSD’s social venture fund reaches next phase
The interpretation technology provider has launched the second batch of its impact investment scheme to tackle the underemployment rate among deaf people in the US.
Alexion flexes muscles with $1.2bn Syntimmune acquisition
Alexion will pay $400m upfront for Baxalta-backed Syntimmune, with up to an additional $800m on offer if the autoimmune disease drug developer hits all its milestones.
PharmEasy formulates $50m funding deal
PharmEasy took its total funding past the $100m mark, six months after collecting some $30m from investors including Manipal Education and Medical Group.